admin – Page 3013 – Get News Story

Protein Alternatives Market Analysis: Key Players, Regional Trends, and Competitive Landscape

“MarketsandMarkets™”

Protein Alternatives Market by Source (Plant Protein, Microbial Protein, Insect Protein), Application (Food & Beverages, Animal Feed, Pet Food), Form, Nature, Production Process (Qualitative), & Region – Global Forecast to 2029

The global protein alternatives market is valued at USD 15.7 billion in 2024 and is projected to grow to USD 25.2 billion by 2029, registering a robust CAGR of 9.9% during the forecast period. This rapid growth is driven by increasing consumer interest in healthier, ethical, and environmentally friendly food options. A surge in demand for alternative proteins—including plant-based, microbial, and insect-derived varieties—reflects a broader shift in dietary preferences influenced by health consciousness, sustainability goals, and food sensitivities.

Protein Alternatives Market

Consumers are moving away from traditional animal-based proteins due to concerns such as allergies, specific dietary restrictions, and the desire for clean, low-calorie, and low-fat nutritional solutions. This has led to a rising preference for plain and unsweetened protein products. The growing awareness of the health benefits associated with alternative proteins—such as reduced risk of chronic diseases—combined with their lower environmental impact compared to conventional meat production, is fueling this transformation.

The market is seeing rapid innovation, with companies exploring ingredients like soy, pea, hemp, quinoa, algae, and various insects to develop a diverse array of protein-rich products. These innovations are not just targeting vegans and vegetarians but also flexitarians and health-conscious consumers seeking to reduce their meat intake. Products like plant-based burgers, insect protein bars, and microbial protein powders are increasingly visible on grocery store shelves and restaurant menus worldwide.

Protein Alternatives Market Growth Drivers

Health and Wellness Trends: Consumers today are more informed and conscious of the impact of food on their health. Protein alternatives often come with lower saturated fats, fewer calories, and no cholesterol, making them an attractive choice for those managing weight, heart conditions, or cholesterol levels.
Sustainability and Environmental Impact: Traditional livestock farming is resource-intensive and contributes significantly to greenhouse gas emissions, deforestation, and water usage. Alternative protein sources such as algae, fungi, and lab-grown meat offer a much lower environmental footprint.
Innovation and Investment: The market is buzzing with innovation, from pea protein burgers and mushroom-based meats to lab-cultivated proteins. Startups and food tech companies are attracting major investments, further fueling research, product development, and commercialization.
Regulatory Support and Label Transparency: Government initiatives supporting sustainable food production and the growing emphasis on clear, clean-label products are also contributing to the surge in demand.

Emerging Segments in the Market

Plant-Based Proteins: Dominant in the market, with soy, pea, and rice proteins leading the way in meat substitutes, dairy alternatives, and nutritional supplements.
Microbial & Fermentation-Based Proteins: Precision fermentation is opening doors to high-efficiency protein production using yeast, bacteria, and fungi.
Insect Protein: Slowly gaining traction for use in animal feed, pet food, and even snacks due to its high protein content and minimal environmental footprint.
Algae & Seaweed: Valued for their rich amino acid profile and omega-3 content, these are emerging in supplements and specialty health products.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=233726079

Dry Form to Lead the Protein Alternatives Market by Form Segment

The dry form segment is projected to maintain a leading position within the form category of the protein alternatives market. This dominance is driven by its exceptional versatility, convenience, and broad consumer appeal. Products such as protein powders and dehydrated alternatives derived from plant sources like soy, peas, and fungi (e.g., mycoprotein) are gaining traction due to their ease of storage, extended shelf life, and seamless integration into diverse food applications—from beverages and snacks to baked goods.

The dry format not only caters to health-conscious consumers seeking clean-label, plant-based options but also offers operational advantages to manufacturers and retailers. Dry protein alternatives minimize storage and transportation costs while requiring less processing and preservation. These benefits align with broader sustainability goals and help reduce environmental impact. As demand for functional, plant-based proteins continues to grow, the dry form segment is expected to drive market innovation and set new industry benchmarks.

Plant-Based Protein: Fastest-Growing Source in the Protein Alternatives Market (2024–2029)

Plant protein is projected to be the fastest-growing source category in the protein alternatives market during the forecast period of 2024 to 2029. Its rise is fueled by increasing consumer awareness around health, environmental sustainability, and ethical sourcing. Unlike animal-derived proteins, plant proteins offer a more eco-friendly and cruelty-free option, resonating with a wide range of dietary and lifestyle preferences.

The versatility of plant sources such as soy, peas, hemp, and algae allows for a diverse portfolio of products, enabling manufacturers to meet varied nutritional and sensory demands. This adaptability fosters rapid innovation, with many plant-based products now rivaling or exceeding traditional proteins in terms of flavor, texture, and health benefits.

In addition, plant proteins are often praised for their efficient digestion and absorption, making them especially appealing to athletes and wellness-focused individuals. With mounting scientific evidence supporting the benefits of plant-based diets—such as reduced risk of chronic diseases—plant protein is poised to continue its strong upward trajectory in the global market.

North America Dominates the Protein Alternatives Market Share.

North America is set to lead the global protein alternatives market, bolstered by advanced food innovation infrastructure, strategic partnerships, and a growing demand for sustainable protein solutions. The region is witnessing significant investment in alternative protein technologies, supported by a consumer base that values health, transparency, and environmental responsibility.

Strategic collaborations underscore North America’s leadership. For instance, ADM (US) partnered with InnovaFeed (France) in January 2022 to supply insect protein for pet food, utilizing waste heat and water resources to enhance sustainability. Similarly, in May 2021, Cargill (US) teamed up with InnovaFeed to integrate insect-based feed into aquaculture and pig diets, highlighting a shift toward innovative protein sources in animal nutrition.

These initiatives reflect North America’s commitment to advancing sustainable food systems through technology and collaboration. As the region continues to drive innovation in both plant- and insect-based protein alternatives, its market dominance is expected to remain strong in the coming years.

Leading Protein Alternatives Companies:

Key market players in this include Tate & Lyle PLC (London), Kerry Group PLC (Ireland), DSM Firmenich (Switzerland), ADM (US), Cargill Incorporated (US), International Flavors & Fragrances Inc. (US), Ingredion (US), Roquette Frères (France), Wilmar International Ltd. (Singapore), Glanbia plc (Ireland), AGT Food and Ingredients (Canada), Tate & Lyle (UK), PURIS (US), Ynsect (France), Global Bugs (Thailand), and Innovafeed (France).

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/alternative-protein-market-233726079.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Protein Alternatives Market Analysis: Key Players, Regional Trends, and Competitive Landscape

Global Clean Label Ingredients Market Outlook 2024–2029: Key Insights from Latest Industry Analysis

“MarketsandMarkets™”

Clean Label Ingredients Market by Ingredient Type (Natural Flavors, Natural Colors, Fruit & Vegetable Ingredients, Starch & Sweeteners, Flours, Malt), Application (Food, Beverages), Form (Dry, Liquid), Certification Type – Global Forecast to 2029

The global clean label ingredients market is projected to grow from USD 50.2 billion in 2024 to USD 69.3 billion by 2029, registering a CAGR of 6.7% during the forecast period. This growth is fueled by rising consumer awareness and the increasing demand for healthier, more transparent food and beverage products. As consumers become more mindful of their dietary choices, they are actively seeking foods made with simple, recognizable ingredients.

Clean Label Ingredients Market

What Are Clean Label Ingredients?

Clean label ingredients are those that are natural, minimally processed, and recognizable by consumers. These typically exclude artificial additives, preservatives, synthetic chemicals, and genetically modified organisms (GMOs). Common examples include:

Natural sweeteners (e.g., stevia, honey)
Plant-based colorants (e.g., beetroot, turmeric)
Natural emulsifiers (e.g., lecithin)
Organic acids and enzymes
Functional flours and whole grains

Clean Label Ingredients Market Drivers

Consumer Awareness and Health Consciousness: A growing number of consumers are concerned about the long-term effects of consuming artificial ingredients. Health-conscious buyers now prefer foods made with short, simple ingredient lists they can understand and trust.
Regulatory Support and Labeling Norms: Governments and regulatory bodies across regions are encouraging truthful labeling and banning the use of certain artificial additives, thus supporting clean label initiatives.
Demand for Transparency: Clean label is no longer a niche trend—it’s a mainstream expectation. Brands are now judged not just on taste and price but on ingredient clarity and sustainability claims.
Rise of Plant-Based and Organic Foods: The surge in vegan, vegetarian, and organic lifestyles has further fueled demand for clean label ingredients, as consumers view plant-based diets as inherently cleaner and more sustainable.

Clean Label Ingredients Market Opportunities: Advancing Natural Ingredients with Functional Benefits

Today’s consumers are looking beyond clean label products—they also expect added health benefits and functional attributes. This shift presents a valuable opportunity for ingredient suppliers and manufacturers to innovate by developing natural ingredients that not only meet clean label standards but also deliver enhanced nutritional and functional value.

There is growing demand for ingredients such as plant-based compounds, fiber-rich additives, and naturally derived components that support better health and meet specific dietary needs. The integration of food science and technology has made it possible to utilize advanced extraction and processing techniques that maintain the nutritional quality of natural ingredients while maximizing their functional properties.

These innovations can improve product texture, stability, and nutritional content—such as fortifying foods with essential vitamins and minerals. By embracing this direction, companies can differentiate their offerings, attract health-conscious consumers, and remain compliant with evolving food regulations.

The development of multifunctional natural ingredients is not only aligned with current consumer preferences but also plays a key role in driving the growth and evolution of the clean label ingredients market.

Rising Demand for Natural, Safe, and Sustainable Products

The clean label trend is also being driven by growing concerns around food safety, health, and sustainability. Shoppers are prioritizing products that are free from artificial additives, preservatives, and GMOs, aligning with a broader shift towards natural and environmentally responsible consumption.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=99427189

Dominance of Prepared Foods & Ready Meals Segment

Among various food applications, the prepared foods and ready meals segment is expected to hold the largest market share throughout the forecast period. This segment’s growth is closely tied to changing consumer lifestyles that demand convenient yet health-focused meal solutions. Consumers now expect ready-to-eat products that are not only quick and easy but also free from synthetic ingredients.

Manufacturers are responding to this shift by reformulating products with clean label ingredients such as natural preservatives, plant-based colorants, and minimally processed components. The prevalence of diet-related health issues—including obesity, diabetes, and food allergies—further reinforces the preference for clean, natural foods.

Dry Form Leads the Market by Form Segment

In 2023, dry-form clean-label ingredients accounted for the largest market share among forms. The convenience, cost-efficiency, and versatility of dry formats make them attractive to both manufacturers and consumers. Dry products, such as powders, are easier to store, transport, and handle compared to liquid or solid alternatives, enabling broad application across functional foods, supplements, and processed foods.

An example of innovation in this space is Symrise’s Diana Food Division, which introduced an organic, clean label, Fair Trade-certified acerola powder in September 2020. This product caters to the growing demand for natural and minimally processed solutions, and is suitable for a range of applications, from dietary supplements to functional beverages.

Germany to Remain a Key Market in Europe

Germany is projected to maintain its leadership in the European clean label ingredients market through 2029. This dominance is underpinned by strong consumer preference for natural and additive-free products, as well as a robust regulatory framework that promotes food safety and transparency. German consumers are known for their scrutiny of food labels and demand for organic and clean products.

Additionally, stringent regulations and proactive enforcement by agencies such as the Federal Office of Consumer Protection and Food Safety (BVL) further support the adoption of clean label ingredients by food manufacturers in the country.

Leading Clean Label Ingredients Companies:

The key players in the market are Cargill, Incorporated (US), ADM (US), DSM (Netherlands), International Flavors & Fragrances Inc. (US), Kerry Group plc (Ireland), BASF SE (Germany), Ingredion (US), Sensient Technologies Corporation (US), Corbion (Netherlands), Symrise (Germany), Chr. Hansen A/S (Denmark), Puratos (Belgium), Ajinomoto Co., Inc. (Japan), Tate & Lyle (UK), and Givaudan (Switzerland).

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Global Clean Label Ingredients Market Outlook 2024–2029: Key Insights from Latest Industry Analysis

Open Day and Free Maths Sessions for Children at Acton Library as Part of Avidator’s Social Impact Initiative

“Bring your child along and spark their love for maths. Join us at Acton Library on 14th June!”

Avidator is hosting free Junior Maths Workshops for Key Stage 2 students as part of its Social Impact Initiative. The event takes place on 14th June 2025 at Acton Town Hall Library, offering fun, curriculum-based learning resources including worksheets, quizzes, and tips guides. Seats are limited, and families are encouraged to attend early.

London, UK – 11 June, 2025 – Avidator, an education-focused organisation, is launching Free Junior Maths Workshops for children in Key Stage 2 (Years 3 to 6). This initiative is part of Avidator’s wider Social Impact Initiative and will be hosted during a special Open Day on:

Day and Date: Saturday, 14th June 2025

Time: 11:00 AM to 12:00 PM

Location: Acton Town Hall Library, Everyone Active Acton Centre, High Street, Acton, London W3 6NE

About the Workshop

The Junior Maths Workshop is designed to provide free educational support to young learners in the local community. The session includes:

1 Tips & Tricks Guide for continued learning at home
5 Curriculum-Based Worksheets
5 Practice Quizzes aligned with Key Stage 2 maths topics

The event is completely free but seating is limited, and parents are encouraged to arrive early to secure a place.

An Initiative to Support Families and Learners

This effort forms part of Avidator’s commitment to educational access and inclusion through its CSR programme. The organisation’s Social Impact Initiative focuses on:

Providing free, hands-on workshops in public libraries and centres
Supporting students aged 7–11 with learning resources that complement school education
Encouraging community-based learning opportunities across London

Explore More on the Day

Families attending the Open Day can:

Speak to Avidator’s education support team
Learn more about 11+ maths coaching available via Avidator’s online platform
Explore future community workshops and support resources

Contact & Further Information

Visit: www.avidator.uk

Call: +44 (0) 20 3151 2082

Location: Acton Town Hall Library, High Street, Acton, London W3 6NE

About Avidator

Avidator is a UK-based education platform supporting children, parents, and schools through accessible learning solutions. Its Social Impact Initiative delivers free learning workshops and resources in local communities, aiming to make education engaging and inclusive for all.

Media Contact
Company Name: Avidator
Contact Person: Jim Cohn
Email: Send Email
Phone: +44 (0) 20 3151 2082
Address:Office 3002, 182-184 High Street North, East Ham
City: London
State: England, E6 2JA
Country: United Kingdom
Website: https://avidator.uk/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Open Day and Free Maths Sessions for Children at Acton Library as Part of Avidator’s Social Impact Initiative

Poultry Medicine/Pharmaceuticals Market to Hit USD 6.68 Billion by 2029 with 5.9% CAGR | MarketsandMarkets™

“The key players in the global poultry medicine/pharmaceuticals market are MSD (US), Elanco (US), Boehringer Ingelheim (Germany), Ceva Sante Animale (France), Zoetis Service LLC (US), Virbac (France), Phibro Animal Health (US), Hester Biosciences Limited (India)”

Browse 500 market data Tables and 56 Figures spread through 424 Pages and in-depth TOC on “Poultry Medicine/Pharmaceuticals Market by Animal Type (Chickens, Turkeys, Ducks), Product (Drugs, Vaccines, Feed Additives), Disease Indication (Newcastle disease, Infectious Bursal Disease, Salmonella), Route of Administration – Global Forecast to 2029

The poultry medicine/pharmaceuticals market valued at US$ 4.73 billion in 2023, is forecasted to grow at a robust CAGR of 5.9%, reaching US$ 5.01 billion in 2024 and an impressive US$ 6.68 billion by 2029.

The growth of the poultry medicine/pharmaceutical industry can be attributed to the rising global population and consumption of poultry meat and eggs leading to more poultry farming practiced notably in the developing regions where poultry is the cheapest source of protein. This growth in poultry medicine/production also brings with it the challenge of disease prevention and control as poultry is often attacked by diseases like Newcastle disease and coccidiosis. Enhanced consumer consciousness, safety concerns and strict law compliance towards the use of antibiotics in food animals have also influenced the market demand in that there is a high demand of vaccines, probiotics, and immune boosters as opposed to antibiotics. In addition to advancements in means of disease control growth enhancing products such as vaccines, in ovo vaccination technology geared towards delivery of vaccines has also worked to enhanced control of diseases among large scale farms. As such, with the emerging regions in Asia, Latin America and Africa increasing poultry production at an exponential rate, the market has also been enhancing towards supplying health solutions for healthy and productive farming dominantly in the sustainable manner.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=112094232

Browse in-depth TOC on “Poultry Medicine/Pharmaceuticals Market“

500 – Tables

56 – Figures

424 – Pages

Based on animal type, the chickens registered the highest share in cold plasma market, people all over the world eat a lot of chicken and eggs, which makes them affordable sources of protein. For this reason, poultry farming has recorded a high level of growth especially in developing economies that have dense populations and elevated rates of urbanization which call for higher levels of production. Moreover, chickens are quite susceptible to other infectious agents such as Newcastle disease, Infectious Bronchitis, and Coccidiosis, which calls for adequate vaccinations and attention to drugs in order to sustain the health and the productiveness of the flock maintained. Also, as poultry farming has a high risk of diseases that have a dramatically negative effect on the economy and the poultry markets, there has been an increase in the measures put on the production of chicken meat and eggs among others. Thus a lot of research and development is being directed by the pharmaceutical companies into the development of products for the chickens which is the leading segment of the poultry medicine/pharmaceuticals market.

Based on product, vaccines hold the most significant market share of the poultry medicine/pharmaceuticals, due to their necessity for controlling diseases, which are integral to large-scale poultry farming. These birds, especially chickens, are prone to highly contagious diseases like Newcastle disease, Infectious Bronchitis, and Avian Influenza. When not controlled, they have the potential to incur the greatest losses. Vaccination is an effective tool that controls these diseases and therefore improves the health of a flock and enhances productivity. In addition, the greater regulatory pressure to reduce the use of antibiotics in livestock production makes poultry producers increasingly rely on vaccines as a means of disease prevention that is not reliant on antibiotics, thus assisting in the fight against problems of antibiotic resistance. Ongoing innovations in vaccine technology, such as in ovo (in-egg) vaccination, make it possible to achieve efficient mass immunization, saving time and labor while improving disease control on large farms. The vaccines are now the most preferred choice in ensuring sustainable control of poultry diseases, hence placing them in the limelight in the poultry medicine/pharmaceuticals market, with a resultant increasing demand for safer poultry products.

Based on disease indication, newcastle disease hold the most significant market share of the poultry medicine/pharmaceuticals, due to its severe economic and production impacts on the global poultry industry. As a highly infectious viral disease, it poses a major threat to flock health, leading to high mortality rates, reduced productivity, and trade restrictions in outbreak scenarios. The live attenuated, inactivated, and recombinant vaccines have dominated this market segment widely. Moreover, increased awareness, government-ordered vaccination programs, and continuous improvement in vaccine technology, such as thermostable and vector-based solutions, continue to strengthen newcastle disease as the prime concern in poultry disease control strategies.

Based on route of administration, the oral route of administration is the most practical, efficient, and economic route for treatment delivery in large flocks. The major reason why poultry producers prefer oral administration is that it is relatively easy to administer the medicine through water or feed; it will ensure all birds receive the necessary dose without the need for individual handling, which would be both labor-intensive and stressful to the birds. This route is especially advantageous in preventive care, wherein drugs such as antibiotics, probiotics, and vitamins can be added to water systems and arrive quickly at the birds’ consumption sites, reducing diseases from spreading among flocks. The oral method can also be delivered flexibly, and its use is better for vaccines, probiotics, and immune boosters that play a vital role in maintaining health and productivity in the flocks. Oral administration is easy and scalable, which places it as the first option for large-scale poultry operations. This cements its foremost position in the poultry medicine/pharmaceuticals market.

Based on region poultry medicine/pharmaceuticals market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Asia-Pacific region has the highest market share of poultry medicine/pharmaceuticals as the poultry industry is experiencing high growth rates, mostly on account of the soaring demand for readily affordable sources of protein like chicken and eggs. Such a demand is also seen across China, India, and Indonesia, primarily supported by the population growth, middle-class expansion, and urbanization of the populace that consumes meat in larger quantities. This demand has been fueled by the increasing number of large-scale poultry farms in the region and the susceptibility of the region to infectious poultry diseases, including Avian Influenza, Newcastle disease, and Infectious Bronchitis.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=112094232

The prominent players in the poultry medicine/pharmaceuticals market are MSD (US), Elanco (US), Boehringer Ingelheim (Germany), Ceva Sante Animale (France), Zoetis Service LLC (US), Virbac (France), Phibro Animal Health (US).

MSD (US)

MSD Animal Health is one of the top companies in the global animal health sector and an important player in the market of poultry pharmaceuticals. With extensive range of products devoted to poultry health, MSD has made inroads in developed markets with vaccines, novel drug delivery systems, and sophisticated disease prevention and treatment modalities. The company’s main objective is improving productivity and animal health, more specifically for the poultry industry the problems of infectious agents, respiratory problems, and growth promotion.

ELANCO (US)

Elanco Animal Health, a global leader in animal health, has established a significant market share in poultry medicine/pharmaceuticals. Elanco’s approach to poultry medicine/pharmaceuticals has allowed it to create a variety of necessary solutions to the critical health needs in poultry farming ranging from infectious diseases to parasite management. The product portfolio of the world leader, it includes antibiotics, vaccines, anticoccidials, parasiticides, nutritional health and other solutions. The product is well accepted in the markets globally and especially in the Americas, Europe and Asia pacific regions. R&D becomes one of the major driver of such growth and new strategies within the company focus on partnering with universities and other biotech companies to enhance the company’s pipeline of products.

BOEHRINGER INGELHEIM (GERMANY)

Boehringer Ingelheim, located in Germany, is one of the major players globally in animal medicines, specifically in the poultry division engaged in the enhancement of poultry health with the help of vaccines, therapeutics, and biosecurity measures. Boehringer Ingelheim’s unyielding focus on R&D is to enhance the Company’s product pipeline especially towards vaccine development and non-antibiotic treatments. In addition, the company has a solid presence across the globe enabling it to operate in different regulatory regimes without any challenges. All these strengths in addition to sustainability and provision of extension services to the farmers enable Boehringer Ingelheim to dominate the global poultry medicine/pharmaceutical market, which has current and future promises of healthy and sustainable poultry production.

For more information, Inquire Now!

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Poultry Medicine/Pharmaceuticals Market to Hit USD 6.68 Billion by 2029 with 5.9% CAGR | MarketsandMarkets™

SyntecBio inc Promising Investment Opportunity in Biotech Sector

As the biotech sector continues to grow at an impressive 7.4% annually, SyntecBio inc is quickly becoming a standout opportunity for investors seeking high-growth potential in emerging biopharma. Leveraging cutting-edge innovation and a robust research pipeline, SyntecBio positions itself at the forefront of next-generation therapeutics, offering a compelling prospect for those looking to capitalize on the sector’s expansion.

Company Overview

Founded in 2016, SyntecBio (https://syntecbiofuel.com) was established with a mission to revolutionize the treatment of rare and chronic diseases through novel biotechnologies. Headquartered in Cambridge, Massachusetts, the company focuses on RNA-based therapeutics and advanced gene-editing platforms, aiming to tackle diseases previously considered untreatable.

SyntecBio’s flagship platform, SynEdit™, utilizes proprietary CRISPR innovations to deliver precise, efficient gene therapies. Complementing this, the company has a diverse pipeline of candidates targeting oncology, rare genetic disorders, and neurodegenerative diseases.

Over the past year, SyntecBio has achieved significant milestones, including the successful completion of a Phase 2 clinical trial for its lead candidate, SYN-101, targeting a rare form of muscular dystrophy. Partnerships with top-tier academic institutions and strategic licensing deals have further solidified its market position, setting SyntecBio apart from its competitors in the biotech investment landscape.

Investment Proposition

For investors, SyntecBio presents a unique growth story in an increasingly competitive biopharma space. The company’s focus on high-need, underserved markets—estimated to be worth over $150 billion globally—offers substantial upside potential.

Although SyntecBio remains privately held, recent financial disclosures indicate strong momentum. The company reported a 40% year-over-year increase in research and development spending, signaling robust pipeline advancement. Analysts following the biotech sector have cited SyntecBio’s diversified product portfolio and innovative platforms as key differentiators, with several investment firms labeling it as a “biotech company to watch.”

Upcoming catalysts include the initiation of Phase 3 trials for SYN-101 in late 2025 and a planned partnership announcement with a major pharmaceutical player. Industry experts also speculate about a potential IPO within the next 12 to 18 months, which could open up broader investment avenues for retail and institutional investors alike.

Market research firm BioMarket Insights recently ranked SyntecBio among the top 20 emerging biopharma companies for 2025, noting its “exceptional technology pipeline and strategic market positioning.” Such endorsements enhance SyntecBio’s profile for those exploring biotech investment opportunities with long-term growth prospects.

Risk Factors

As with any emerging biotech investment, risks are inherent. SyntecBio operates in a highly competitive market dominated by established pharmaceutical giants. Success in clinical trials is not guaranteed, and regulatory approval processes can be lengthy and unpredictable.

Additionally, the adoption of advanced therapies such as gene editing may face technological and ethical hurdles, potentially impacting market acceptance. Investors should carefully consider these factors and conduct thorough due diligence before making investment decisions.

How to Invest

Currently, investment opportunities in SyntecBio are available through private placements targeting accredited investors, with minimum investments starting at $50,000. The company’s shares are not yet publicly traded, but a future IPO could provide retail investors with access. Interested parties can find more information and investment prospectuses on SyntecBio’s official investor relations website.

For those seeking early exposure to a company at the cutting edge of biotech innovation, SyntecBio represents a potentially rewarding, though high-risk, addition to a diversified investment portfolio.

Syntec Biofuel Overview

Syntec Biofuel Inc is a clean technology company specializing in renewable biofuels. The company’s mission is to develop and commercialize technologies that convert biomass and waste materials into clean, sustainable fuel alternatives such as ethanol, methanol, and other biofuels.

Their core technology focuses on gasification and catalytic conversion processes, enabling the transformation of non-food biomass—like wood waste and agricultural residues—into valuable biofuels. This provides an environmentally friendly alternative to fossil fuels, contributing to carbon emission reductions and energy diversification.

Syntec Biofuel aims to position itself in the growing renewable energy sector, aligning with global trends towards sustainable and green energy solutions.

Media Contact
Company Name: Syntec Biofuel UK Ltd.
Contact Person: Dr. Eleanor Matthews (Head of Research & Partnerships)
Email: Send Email
Phone: +44 (0)20 7946 0823
Address:23 Innovation Crescent, Cambridge Science Park
City: Cambridge, CB4 0GA
Country: United Kingdom
Website: https://syntecbiofuel.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SyntecBio inc Promising Investment Opportunity in Biotech Sector

Pedals Bike Rentals Shares Safety Tips for a Fun and Worry-Free Ride on Hilton Head Island

Stay Safe and Explore Confidently with These Expert Guidelines from Hilton Head’s Trusted Bike Rental Company

Hilton Head Island, SC – June 11, 2025 – As biking continues to be one of the most popular and eco-friendly ways to explore Hilton Head Island, Pedals Bike Rentals is encouraging visitors and locals to ride smart with a timely reminder of bicycle safety best practices. Whether you’re pedaling down the beach, cruising through neighborhoods, or exploring the island’s 60+ miles of paved paths, a little preparation goes a long way in ensuring a safe and enjoyable experience.

Top Safety Tips for Hilton Head Cyclists

Pedals Bike Rentals, which has served the island community since 1981, offers the following tips to help riders of all ages stay safe this season:

Wear a Helmet: Helmets are the first line of defense in an accident. Pedals offers helmet rentals upon request.
Use Lights and Reflectors: Especially important for early morning or evening rides. Stay visible to drivers and pedestrians.
Ride on Designated Paths: Stick to bike paths when available, and avoid riding on busy roads or sidewalks.
Follow Traffic Rules: Obey all stop signs and signals, and ride in the same direction as traffic.
Use Hand Signals: Clearly communicate your intentions to turn or stop to nearby cyclists and motorists.
Stay Alert: Keep headphones out and eyes ahead. Be aware of other cyclists, pedestrians, and vehicles.
Secure Your Bike: Pedals includes a bike lock with every rental to help prevent theft when you’re off exploring.

Pedals Makes Safety Easy

All bikes at Pedals Bike Rentals are regularly maintained and safety-checked by expert mechanics. From beach cruisers and electric bikes to youth bikes and kiddie karts, customers can rest assured that they’re riding equipment they can trust.

Plan a Safe and Scenic Ride Today

Whether you’re a first-time visitor or a longtime Hilton Head resident, safety should always come first. Visit www.pedalsbicycles.com to book your bike rental, review riding guidelines, and make the most of your Lowcountry adventure!

Media Contact
Company Name: Pedals Bicycles
Contact Person: Nick Wall
Email: Send Email
Phone: (866) 942-4985
Address:71 Pope Ave A
City: Hilton Head Island
State: South Carolina
Country: United States
Website: https://www.pedalsbicycles.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pedals Bike Rentals Shares Safety Tips for a Fun and Worry-Free Ride on Hilton Head Island

Closed Systems Transfer Devices Market worth US$2.09 billion by 2030 with 7.0% CAGR | MarketsandMarkets™

“The key players in the global closed system transfer devices market include BD (US), ICU Medical, Inc. (US), EQUASHIELD (US), Corning Incorporated (US), Simplivia Healthcare Ltd. (Israel), JMS (Japan)”

Browse 273 market data Tables and 65 Figures spread through 289 Pages and in-depth TOC on “Closed Systems Transfer Devices Market by Closing Mechanism (Color-to-Color Systems), Type (Needleless Systems), Component (Female Components, Male Luers), Technology (Air Cleaning/Filtration Devices), End User (Hospitals & Clinics) – Global Forecast to 2030

The global Closed System Transfer Devices Market, valued at US$1.35 billion in 2024, is forecasted to grow at a robust CAGR of 7.0%, reaching US$1.49 billion in 2025 and an impressive US$2.09 billion by 2030. The closed system transfer devices market has been consistently increasing because of heightened awareness of the risks involved in working with hazardous drugs and the requirement for robust safety protocols within healthcare facilities. The reasons include stringent regulations, heightened concerns about worker safety, and a rise in cancer cases that fuel the use of chemotherapy drugs. In this report, the market is divided into closing mechanism, type, component, technology, end user, and region.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=251802928

Browse in-depth TOC on “Closed Systems Transfer Devices Market“

273 – Tables

65 – Figures

289 – Pages

By Based on type, the closed system transfer devices market is categorized into membrane-to-membrane systems and needleless systems. In 2023, the membrane-to-membrane systems segment held the largest share, by type. The high share and fast growth of this segment are due to their ease of use and lower rate of contamination with double-membrane containment systems. Membrane-to-membrane systems offer higher safety by forming a fully isolated environment during drug transfer.

By technology, the closed system transfer devices market is bifurcated into diaphragm-based devices, compartmentalized devices, and air cleaning/filtration devices. In 2023, the share of the diaphragm-based devices segment was the highest at 43.0%. Diaphragm-based devices tend to be compatible with a wide variety of drug delivery systems and container closures, making them versatile for different clinical uses. They offer flexibility for handling hazardous drugs.

By geography, North America held the largest market share of the closed system transfer devices market in 2024 due to the ongoing research & development of innovative CSTD technologies and better safety, efficiency, and user experience. Additionally, tight regulations over handling hazardous drugs within healthcare environments necessitate the employment of CSTDs to ensure that there is reduced risk exposure to hazardous drugs. Enforcement of these regulations spurs the use of CSTDs within the region.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=251802928

The key players in the global closed system transfer devices market include BD (US), ICU Medical, Inc. (US), EQUASHIELD (US), Corning Incorporated (US), Simplivia Healthcare Ltd. (Israel), JMS (Japan), Baxter (US), Terumo Corporation (Japan), Cardinal Health (US), B Braun Melsungen AG (Germany), West Pharmaceuticals Services, Inc. (US), CODAN Medizinische Geräte GmbH (Germany), Yukon Medical (US), and INSUNG MEDICAL Co., Ltd. (South Korea).

ICU Medical, Inc. (US):

ICU Medical, Inc. has a comprehensive portfolio for the safe handling of dangerous IV medications. Its range of products includes automated and needleless drug compounding systems. The company is engaged in a long-term supply deal with Terumo Corporation (Japan) to distribute its products throughout Japan and Asia, including IV therapy and CSTD products. Over the last three years, the company’s infusion consumables segment has grown steadily, taking up the highest share of 37% of the total revenue mix.

BD (US):

BD has a broad product portfolio, including hazardous drug-safe devices such as the PhaSeal and Texium system. It has a global presence spanning more than 50 countries. The BD PhaSeal system works with a wide range of chemotherapeutic medications. It is more widely used in the US and other markets than other CSTDs.

For more information, Inquire Now!

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Closed Systems Transfer Devices Market worth US$2.09 billion by 2030 with 7.0% CAGR | MarketsandMarkets™

TLC Supply to Celebrate One-Year Anniversary at New Braintree Location in June

Braintree, MA – June 11, 2025 – TLC Supply, Inc., a leading masonry and hardscape supplier serving Massachusetts, Rhode Island, and Southern New Hampshire, is proud to celebrate the one-year anniversary of its successful relocation to a newly expanded facility at 48 Arnold Street, Braintree, MA 02184. This move marked a new chapter in the company’s continued growth and commitment to serving contractors, masons, municipalities, and homeowners with exceptional products and customer service.

A family-owned business, TLC Supply has spent the last year expanding its offerings and enhancing its customer experience from its new, conveniently located and fully updated facility. The Braintree site boasts a beautiful office and showroom, along with a 3,000 square foot outdoor patio display—allowing customers to explore a wide range of products and envision their next project in a hands-on environment.

“The past year at our new Braintree location has been incredibly rewarding,” states Don Ross, founder and owner of TLC Supply. “This expansion has enabled us to better serve our customers with a wider selection of materials, enhanced displays, with the same dedication to expert service. This facility has allowed us to better showcase our products, increase inventory, and improve delivery logistics—all while maintaining the personalized service and expert product guidance our customers have come to expect.”

From top-tier brands of pavers, retaining walls, and natural stone veneers to custom-fabricated lintels, sills, and stone cuts, TLC Supply is known for helping both professionals and DIYers bring their hardscape visions to life. With a full fleet of delivery trucks, the company provides fast, reliable service across the region.

TLC Supply offers a comprehensive range of industry-leading brands and products, including:

Hardscaping: Pavers, retaining walls, granite, bluestone, limestone, porcelain, aggregates and sand.
Masonry: Bricks, concrete blocks, natural stone veneer, bagged cements, repair mortars, chimney flues and caps, masonry cleaners, and sealers.
Rebar & Other Concrete Reinforcement: Rebar cut to size, rebar bending, tie chairs and rebar ties as well as Dur-O-Wall, wire lath, wire mesh and steel angle iron.
Custom Fabrication & Services: Concrete lintels, sills, and splash blocks fabrication, state-of-the-art stone cutting to exact specifications and personalized engraving services.

TLC Supply is also a Massachusetts Department of Environmental Protection Certified Recycling Facility for used brick, block, concrete, and gravel.

Whether you’re embarking on a large-scale commercial development or enhancing your home’s outdoor living space, TLC Supply invites you to visit their Braintree location to experience the “TLC Supply difference” where quality, expertise, and customer satisfaction are the cornerstones of their business.

About TLC Supply, Inc.

TLC Supply, Inc. is a family-owned hardscape and masonry supplier dedicated to providing top-quality materials and expert service to general contractors, masons, architects, towns/municipalities, and homeowners throughout Massachusetts, Rhode Island, and Southern New Hampshire. Operating from their expanded location in Braintree, MA, TLC Supply offers a complete range of hardscaping and masonry products, custom fabrication services, and efficient delivery to help customers get the job done right. Their commitment to quality, expertise, and customer satisfaction sets them apart in the industry.

For more information, visit www.tlcsupply.com.

Media Contact
Company Name: TLC Supply, Inc.
Contact Person: Rolanda Ross
Email: Send Email
Phone: (781) 380-0768
Address:48 Arnold Street
City: Braintree
State: MA
Country: United States
Website: https://www.tlcsupply.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: TLC Supply to Celebrate One-Year Anniversary at New Braintree Location in June

Sodium-Ion Battery Market Size Analysis, Competitive Insights, Leading Players and Growth Opportunities by 2030 | Top key Players Analysis

Sodium-ion batteries are gaining momentum as a cost-effective and sustainable alternative to lithium-ion technology, especially for grid storage. Key players like CATL, Faradion, Natron Energy, and HiNa Battery are accelerating innovation, driving global market expansion and scalability.

The global sodium-ion battery market is projected to grow from USD 0.67 billion in 2025 to USD 2.01 billion by 2030, at a CAGR of 24.7% during the forecast period. The research report provides access to critical information such as sodium-ion battery market growth drivers, market growth restraints, current market trends and top 10 key players analysis. The market is expected to grow, fueled by their affordability compared to lithium-ion batteries. This makes them perfect for large-scale energy storage, especially with renewables like wind and solar needing solutions for fluctuating power. Their reliance on common sodium positions them as a more sustainable option, pushing the market forward due to the global focus on reducing our environmental impact.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=207269067

The automotive sodium-ion battery market, by end-use, is expected to be the fastest-growing market during the forecast period

Despite the energy storage sector driving the overall sodium-ion battery market, the automotive industry currently takes the lead in using these batteries. This dominance is attributed to their significant cost advantage compared to lithium-ion batteries in electric vehicles and their sufficient energy density for many everyday EV applications. This affordability opens doors to more budget-friendly EVs, potentially expanding the market and boosting overall demand for batteries. High demand is expected for the sodium-ion battery for the automotive sector during the forecast period.

The non-aqueous technology segment is projected to lead the global sodium-ion battery market during the forecast period

The non-aqueous technology is expected to be one of the major segments of the sodium-ion battery market. Factors driving this technology are organic solvents in these electrolytes which allow for higher voltages and thus greater energy density, perfect for electric vehicles needing extended range. They eliminate safety risks associated with water-based electrolytes and sodium metal and offer superior performance stability across varying temperatures, making them more reliable for demanding applications. While aqueous options are being explored due to their environmental benefits, these factors currently secure non-aqueous electrolytes, which supports the growth of the sodium-ion battery market.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=207269067

Asia Pacific is projected to be the largest sodium-ion battery market

Asia Pacific is the largest consumer of sodium-ion batteries, in terms of value. The market in the region is driven by a combination of factors, such as economic powerhouses like China and India, which are experiencing rapid growth, boosting the demand for electricity. The adoption of renewable energy is also on the rise, requiring efficient storage solutions that sodium-ion batteries can provide. Government backing in research and production further fuels the region’s leadership, while a growing population with disposable income fuels the electric vehicle market, another key application for these batteries that is expected to boost the market.

Sodium-ion Battery Companies

Some of the leading players in this market include Faradion (UK), Contemporary Amperex Technology Co., Ltd. (China), TIAMAT Energy (France), HiNa Battery Technology Co., Ltd. (China), Jiangsu Zoolnasm Energy Technology Co., Ltd. (China), NGK Insulators Ltd (Japan), Li-FUN Technology Corporation Limited (China), Zhejiang Natrium Energy Co., Ltd. (China), Natron Energy, Inc. (US), Jiangsu Transimage Sodium-lon Battery Technology Co., Ltd. (China) and Altris AB (Sweden), among others.

Faradion (UK)

Faradion is a subsidiary of Indian Reliance Industries and leads in the sodium-ion battery technology as the world’s first company manufacturing non-aqueous sodium-ion batteries. Its innovative solutions offer advantages over traditional lithium-ion and lead-acid batteries, delivering high performance at lower costs with enhanced safety features and a wider operating temperature range. Faradion’s sodium-ion batteries can be cycled to and stored at zero volts, ensuring safer cells and reduced costs. With impressive energy density, power capability, cycle life, and energy efficiency, these batteries find applications in energy storage, transportation, backup power, and remote energy needs. Reliance has acquired 100% stake in Faradion. It has a global presence across Europe, North America, South America, and Africa.

Contemporary Amperex Technology Co., Ltd. (China)

Contemporary Amperex Technology Co., Ltd. (CATL) specializes in the manufacture of sodium-ion batteries. CATL is a global leader in new energy technologies, specializing in EV and energy storage batteries. With a focus on replacing fossil fuels, CATL promotes the adoption of clean energy and electrification intelligence. Offering high energy density, long life cycles, and safety features, CATL’s EV batteries are customizable to meet diverse customer needs. Its energy storage batteries support the integration of renewable energy and various applications. Through battery material recycling, CATL ensures resource sustainability. The company has also released its first-generation sodium-ion battery. Currently it has a target of a 20 GWh production capacity by 2030. The company operates five sodium-ion battery research & development centers, four in China and one in Europe. The company also operates 13 production bases with a presence across the Asia Pacific, Europe, and North America.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=207269067

TIAMAT Energy (France)

TIAMAT Energy provides pioneering inventive solutions for energy storage needs. Focused on design, development, and production, TIAMAT specializes in leveraging the Na-ion technology within its 18650 cells, offering exceptional attributes for power demands, rapid charging, and prolonged cycle longevity. TIAMAT Energy focuses on designing, developing, and manufacturing sodium-ion batteries for mobility and stationary energy storage. They emphasize the stability, simplicity, safety, speed, and performance of their battery technology. Its features include fast charging in 5 minutes, high power density ranging from 2-5kW/kg, a long lifetime of 5,000+ cycles up to 80% of capacity, and a high level of safety. TIAMAT Energy’s product portfolio includes innovative solutions for energy storage applications, focusing on the sodium-ion battery technology. At the end of 2023, TIAMAT Energy initiated its first 6 GWh-scale sodium-ion battery production line, and an additional 6 GWh is expected by 2030. The company has a presence only across Europe.

Hina Battery Technology Co., Ltd. (China)

HiNa Battery Technology Co., Ltd. is a pioneering manufacturing company dedicated to the advancement and production of sodium-ion batteries. With a specialized focus on sodium-ion technology, HiNa Battery is at the forefront of innovation in the energy storage industry. It operates through three business segments, namely, Energy Storage Systems, Research & Development, and Market Focus. The Energy Storage Systems segment manufactures a new generation of energy storage systems, particularly sodium-ion batteries. It serves various industries, including chemical and automotive.

Jiangsu Zoolnasm Energy Technology Co., Ltd (China)

Jiangsu Zoolnasm Energy Technology Co Ltd. focuses on the development and production of sodium-ion batteries. Founded in January 2021 and located in Suzhou, Jiangsu province in China, the company is at the forefront of the sodium-ion battery technology. Zoolnasm’s sodium-ion battery manufacturing base project in Guangde, Anhui province, marks an important milestone for the industry, being the world’s first mass production base for polyanionic sodium iron sulfate sodium-ion batteries.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sodium-Ion Battery Market Size Analysis, Competitive Insights, Leading Players and Growth Opportunities by 2030 | Top key Players Analysis

Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™

“Key players in the oral proteins and peptides market include Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc. (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc. (Canada), CHIESI Farmaceutici S.p.A. (Italy), EnteraBio Ltd. (Israel)”

Browse 407 market data Tables and 53 Figures spread through 323 Pages and in-depth TOC on “Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) – Global Forecast to 2030

The global Oral Proteins & Peptides Market , valued at US$7.35 billion in 2024, is forecasted to grow at a robust CAGR of 22.1%, reaching US$8.85 billion in 2025 and an impressive US$24.00 billion by 2030. This growth is driven by several factors, including the rising prevalence of chronic diseases such as diabetes, gastrointestinal disorders, and kidney diseases. Additionally, advancements in drug delivery technologies and patient preference for oral medication administration contribute to this market expansion.

Semaglutide, a GLP-1 receptor agonist, has captured a significant share of the market, primarily due to the increasing rates of diabetes, obesity, and overweight individuals. Furthermore, Novo Nordisk A/S, based in Denmark, has announced the development of another GLP-1 receptor agonist molecule aimed at treating obesity and overweight conditions. These factors are also expected to drive market growth in the coming years.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=194705708

Browse in-depth TOC on “Oral Proteins & Peptides Market“

410 – Tables

52 – Figures

323 – Pages

By semaglutide segment, the oral proteins and peptides market is segmented by molecule into several categories, including trofinetide, semaglutide, linaclotide, voclosporin, plecanatide, calcitonin, and others. In 2024, the semaglutide segment dominated the market and is expected to continue leading throughout the forecast period. The strong growth of this segment can be attributed to several factors, such as the increasing prevalence of diabetes and the rising demand for oral proteins and peptides due to their benefits, including ease of use and high patient compliance. Semaglutide is an analog of glucagon-like peptide-1 (GLP-1), a hormone crucial in regulating blood sugar levels and appetite. It is primarily used for managing type 2 diabetes.

By tablets segment, the oral proteins and peptides market is segmented based on formulation into tablets, capsules, and oral solutions. Among these, the tablets segment is expected to experience the highest growth rate during the forecast period. Several key factors contribute to this growth, including the advantages offered by tablets, such as precise drug dosing, greater stability compared to capsules, a longer shelf life, ease of use, and affordability. Additionally, these formulations allow for controlled release, which enhances bioavailability and ensures consistent therapeutic effects. Tablets are also cost-effective to manufacture and distribute, promoting wider accessibility and scalability in commercial production.

By geography, the oral proteins and peptides market is divided into six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Europe is the second-largest market for oral proteins and peptides globally. Several key factors contribute to the growth of this market. These include the strong presence of major players offering oral proteins and peptides, a favourable regulatory environment, and the wide availability of these products in the region, with reimbursement options provided in several countries.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=194705708

Key players in the oral proteins and peptides market include Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc. (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc. (Canada), CHIESI Farmaceutici S.p.A. (Italy), EnteraBio Ltd. (Israel), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), R-Pharm JSC (Russia), Proxima Concepts (US), SWK Holdings Corporation (US), AstraZeneca (UK), Regor Therapeutics Group (China), Viking Therapeutics (US), Protagonist Therapeutics Inc. (US), Rani Therapeutics Holdings, Inc. (US), Carmot Therapeutics, Inc. (US), Terns Pharmaceuticals, Inc. (US), Structure Therapeutics (US), Zealand Pharma (Denmark), Sciwind Biosciences (China), and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China).

Novo Nordisk A/S (Denmark):

Novo Nordisk A/S is headquartered in Denmark and is a leading pharmaceutical company globally, particularly in the area of antidiabetic medications. With its extensive product portfolio, wide geographic presence, and well-established global brand, the company has successfully positioned itself as a market leader. Its focused research and manufacturing capabilities, especially regarding insulins and GLP-1 products—such as RYBELSUS—have played a significant role in its success. The company has increased its share of the global GLP-1 therapy market to 55.3% as of the first quarter of 2024, up from 50.8% in 2021. Last year, Novo Nordisk allocated USD 4.7 billion to research & development, which has strengthened its market position, largely due to its development of oral versions of existing drugs like semaglutide, which have significant potential applications.

AbbVie Inc. (US):

AbbVie Inc. holds the second position among US pharmaceutical companies specializing in oral proteins and peptides. The company offers oral peptides such as linaclotide and has focused intensively on other products like atogepant and Ubrogepant, positioning itself to capture a significant share of the market. Through its strategic emphasis on gastrointestinal diseases, AbbVie has successfully maintained its competitive edge, notably with linaclotide. Additionally, AbbVie has been proactive in forming strategic partnerships and collaborations to enhance its portfolio of oral proteins and peptides. These partnerships with biotech firms, academic institutions, and contract research organizations (CROs) allow the company to access cutting-edge technologies and innovative delivery methods, further expanding its presence in the market.

Pfizer Inc. (US):

Pfizer Inc. is one of the leading global health companies based in the US. The company entered the oral peptides market with NURTEC ODT, a CGRP receptor antagonist used to treat episodic migraines. Pfizer’s pipeline appears robust; one notable drug in development is Danuglipron, an oral GLP-1 receptor agonist currently in Phase II clinical trials. Pfizer also focuses on strategic business acquisitions to strengthen its portfolio. For instance, NURTEC ODT became part of Pfizer’s offerings by acquiring Biohaven Pharmaceutical in October 2022.

For more information, Inquire Now!

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™